Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease - PubMed (original) (raw)
Case Reports
Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease
Grace M Lloyd et al. Acta Neuropathol Commun. 2020.
Abstract
The discovery of mutations associated with familial forms of Alzheimer's disease (AD), has brought imperative insights into basic mechanisms of disease pathogenesis and progression and has allowed researchers to create animal models that assist in the elucidation of the molecular pathways and development of therapeutic interventions. Position 717 in the amyloid precursor protein (APP) is a hotspot for mutations associated with autosomal dominant AD (ADAD) and the valine to isoleucine amino acid substitution (V717I) at this position was among the first ADAD mutations identified, spearheading the formulation of the amyloid cascade hypothesis of AD pathogenesis. While this mutation is well described in multiple kindreds and has served as the basis for the generation of widely used animal models of disease, neuropathologic data on patients carrying this mutation are scarce. Here we present the detailed clinical and neuropathologic characterization of an APP V717I carrier, which reveals important novel insights into the phenotypic variability of ADAD cases. While age at onset, clinical presentation and widespread parenchymal beta-amyloid (Aβ) deposition are in line with previous reports, our case also shows widespread and severe cerebral amyloid angiopathy (CAA). This patient also presented with TDP-43 pathology in the hippocampus and amygdala, consistent with limbic predominant age-related TDP-43 proteinopathy (LATE). The APOE ε2/ε3 genotype may have been a major driver of the prominent vascular pathology seen in our case. These findings highlight the importance of neuropathologic examinations of genetically determined AD cases and demonstrate striking phenotypic variability in ADAD cases.
Keywords: APOE; Alzheimer’s disease; Amyloid precursor protein; Beta-amyloid; Cerebral amyloid angiopathy; London mutation.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Fig. 1
(a) Representative chromatogram of Sanger-sequencing revealed a guanine-to-adenine single nucleotide substitution at codon 717 of APP, resulting in a Valine to Isoleucine amino acid change in the ADAD patient (APP NM_000484.3 c2149G > A pVal717Ile). (b, c) Representative gross images of formalin-fixed left hemibrain. (d - f) Representative overview (scale bar = 2000 μm) and high magnification (insert, scale bar = 50 μm) images of H&E stained sections reveal neuron loss, astrogliosis and numerous neuritic plaques (d), superficial spongiosis (e), as well as substantial amyloid angiopathy of superficial cortical and leptomeningeal vessels (f)
Fig. 2
Representative images of 4G8-stained sections of mid-frontal cortex (a), superior temporal gyrus (b), visual cortex (c), cingulate gyrus (d), amygdala (e) and cerebellum (f) reveal widespread parenchymal and vascular (inserts) Aβ-pathology throughout the neuroaxis. Cerebral amyloid angiopathy was more prominent in cortical and leptomeningeal vasculature with no substantial involvement of cortical capillaries. Overview images (scale bar = 1000 μm) and high magnification insert (scale bar = 50 μm)
Fig. 3
Representative overview (scale bar = 2000 μm) and high magnification (insert, scale bar = 50 μm) images of AT8 staining in APP V717I mutation carrier for the hippocampus (a), superior temporal gyrus (b) and visual cortex (c) reveal substantial NFT pathology in all regions examined. (d) AT8 staining also reveals “frequent” neuritic plaques in the inferior temporal cortex (scale bar = 1000 μm, insert scale bar = 50 μm). Representative overview (scale bar = 2000 μm) and high magnification (insert, scale bar = 50 μm) images of TDP-43 staining demonstrate TDP-43 positive inclusions in hippocampus (e) and amygdala (f)
Fig. 4
(a - c) Representative images of superior temporal cortex sections of APP V717I mutation carrier labelled with pan-Aβ (4G8, a) antibodies, demonstrate strong labeling of parenchymal and vascular amyloid deposits. Vascular deposits also showed strong staining with Aβ1–42 specific antibodies (12F4, b) and Aβ1–40 specific antibodies (13.1.1, c). Parenchymal amyloid deposits demonstrated strong Aβ1–42 positivity (12F4, b), while being scarcely labelled with Aβ1–40 specific antibodies (13.1.1, c). Vascular amyloid in two SAD cases with different APOE genotype (ɛ3/ɛ3 (d-f) and ɛ4/ɛ4 (g-i)), showed a similar staining pattern with strong positivity for pan-Aβ antibodies (4G8, d, g), as well as Aβ1–42 (e, h) and Aβ1− 40 specific antibodies (f, i). Parenchymal amyloid in SAD cases were highlighted with pan-Aβ (d, g) and Aβ1–42 specific antibodies (e, h), and showed some reactivity with Aβ1–40 specific antibodies (f, i). Overview images (scale bar = 100 μm)
Similar articles
- Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome.
Kasri A, Camporesi E, Gkanatsiou E, Boluda S, Brinkmalm G, Stimmer L, Ge J, Hanrieder J, Villain N, Duyckaerts C, Vermeiren Y, Pape SE, Nicolas G, Laquerrière A, De Deyn PP, Wallon D, Blennow K, Strydom A, Zetterberg H, Potier MC. Kasri A, et al. Acta Neuropathol. 2024 Jul 18;148(1):8. doi: 10.1007/s00401-024-02756-4. Acta Neuropathol. 2024. PMID: 39026031 Free PMC article. - Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
Vidal R, Calero M, Piccardo P, Farlow MR, Unverzagt FW, Méndez E, Jiménez-Huete A, Beavis R, Gallo G, Gomez-Tortosa E, Ghiso J, Hyman BT, Frangione B, Ghetti B. Vidal R, et al. Acta Neuropathol. 2000 Jul;100(1):1-12. doi: 10.1007/s004010051186. Acta Neuropathol. 2000. PMID: 10912914 - Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease.
Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A, Jones M, Snowden JS, Pendleton N, Potier MC, Laquerrière A, Prasher V, Iwatsubo T, Strydom A. Mann DMA, et al. Acta Neuropathol. 2018 Oct;136(4):569-587. doi: 10.1007/s00401-018-1866-3. Epub 2018 May 16. Acta Neuropathol. 2018. PMID: 29770843 Free PMC article. - Alzheimer's disease families with amyloid precursor protein mutations.
Rossor MN, Newman S, Frackowiak RS, Lantos P, Kennedy AM. Rossor MN, et al. Ann N Y Acad Sci. 1993 Sep 24;695:198-202. doi: 10.1111/j.1749-6632.1993.tb23052.x. Ann N Y Acad Sci. 1993. PMID: 8239283 Review. - LATE-NC in Alzheimer's disease: Molecular aspects and synergies.
Tomé SO, Gawor K, Thal DR. Tomé SO, et al. Brain Pathol. 2024 Jul;34(4):e13213. doi: 10.1111/bpa.13213. Epub 2023 Oct 4. Brain Pathol. 2024. PMID: 37793659 Free PMC article. Review.
Cited by
- Urine-derived cells from the aged donor for the 2D/3D modeling of neural cells via iPSCs.
Supakul S, Hatakeyama Y, Leventoux N, Itsuno M, Numata N, Hiramine H, Morimoto S, Iwata A, Maeda S, Okano H. Supakul S, et al. Aging Brain. 2023 Nov 19;4:100101. doi: 10.1016/j.nbas.2023.100101. eCollection 2023. Aging Brain. 2023. PMID: 38045491 Free PMC article. - Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer's disease.
Barmaki H, Nourazarian A, Khaki-Khatibi F. Barmaki H, et al. Front Aging Neurosci. 2023 Nov 2;15:1281338. doi: 10.3389/fnagi.2023.1281338. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38020769 Free PMC article. Review. - Mammalian Models in Alzheimer's Research: An Update.
Sharma H, Chang KA, Hulme J, An SSA. Sharma H, et al. Cells. 2023 Oct 16;12(20):2459. doi: 10.3390/cells12202459. Cells. 2023. PMID: 37887303 Free PMC article. Review. - Modeling Cellular Crosstalk of Neuroinflammation Axis by Tri-cultures of iPSC-Derived Human Microglia, Astrocytes, and Neurons.
Connolly K, Lehoux M, Assetta B, Huang YA. Connolly K, et al. Methods Mol Biol. 2023;2683:79-87. doi: 10.1007/978-1-0716-3287-1_7. Methods Mol Biol. 2023. PMID: 37300768 - Clinical considerations in early-onset cerebral amyloid angiopathy.
Banerjee G, Collinge J, Fox NC, Lashley T, Mead S, Schott JM, Werring DJ, Ryan NS. Banerjee G, et al. Brain. 2023 Oct 3;146(10):3991-4014. doi: 10.1093/brain/awad193. Brain. 2023. PMID: 37280119 Free PMC article. Review.
References
- Akiyama H, Mori H, Sahara N, Kondo H, Ikeda K, Nishimura T, Oda T, McGeer PL. Variable deposition of amyloid β-protein (Aβ) with the carboxy- terminus that ends at residue valine40 (Aβ40) in the cerebral cortex of patients with Alzheimer’s disease: a double-labeling immunohistochemical study with antibodies. Neurochem Res. 1997;22:1499–1505. doi: 10.1023/A:1021910729963. - DOI - PubMed
- Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, Leyton-Cifuentes D, Chen K, Baena A, Aguillon D, Rios-Romenets S, Giraldo M, Guzmán-Vélez E, Norton DJ, Pardilla-Delgado E, Artola A, Sanchez JS, Acosta-Uribe J, Lalli M, Kosik KS, Huentelman MJ, Zetterberg H, Blennow K, Reiman RA, Luo J, Chen Y, Thiyyagura P, Su Y, Jun GR, Naymik M, Gai X, Bootwalla M, Ji J, Shen L, Miller JB, Kim LA, Tariot PN, Johnson KA, Reiman EM, Quiroz YT (2019) Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med 25. 10.1038/s41591-019-0611-3 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- RF1 AG051504/NH/NIH HHS/United States
- R01 AG061796/NH/NIH HHS/United States
- RF1 AG051504/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- R01 AG061796/AG/NIA NIH HHS/United States
- U01 AG046139/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- U01 AG046139/NH/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous